March 2, 2021

A Shorter Symptom-Onset to Remdesivir Treatment (SORT) Interval Is Associated with a Lower Mortality in Moderate-to-Severe COVID-19: A Real-World Analysis

Category: Article Summary

Topic: Testing and Treatment

Keywords (Tags): treatment

• In a retrospective analysis of patients with moderate-to-severe COVID-19 in India (n=346), patients receiving remdesivir 9 days or less after symptom onset had significantly lower all-cause mortality compared to those who received it after 9 days (18% vs 34%). Odds of death were reduced by 37% among patients receiving remdesivir <=9 days post-symptom onset compared to those receiving it after 9 days. All patients also received corticosteroids.

Mehta et al. (Feb 26, 2021). A Shorter Symptom-Onset to Remdesivir Treatment (SORT) Interval Is Associated with a Lower Mortality in Moderate-to-Severe COVID-19: A Real-World Analysis. International Journal of Infectious Diseases. https://doi.org/10.1016/j.ijid.2021.02.092